Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept for Remission Maintenance in ANCA-associated Vasculitis
NCT05965284Phase 4Recruiting
- Sponsor
- Chinese SLE Treatment And Research Group
- Start
- Mar 2023
- Primary completion
- Dec 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of telitacicept in Antineutrophil cytoplasmic antibody-associated vasculitis (AAV), sponsored by Chinese SLE Treatment And Research Group. Started Mar 2023; status: recruiting.
02
Drugs
telitacicept
03
Conditions
Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT05965284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05965284.